Victory Capital Management Inc. Acquires Shares of 12,658 Co-Diagnostics, Inc. (NASDAQ:CODX)

Victory Capital Management Inc. acquired a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 12,658 shares of the company’s stock, valued at approximately $104,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CODX. Credit Agricole S A acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $48,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $99,000. Goldman Sachs Group Inc. acquired a new stake in Co-Diagnostics during the 1st quarter valued at approximately $109,000. Cannon Global Investment Management LLC acquired a new stake in Co-Diagnostics during the 2nd quarter valued at approximately $135,000. Finally, Cubist Systematic Strategies LLC lifted its stake in Co-Diagnostics by 35.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 21,390 shares of the company’s stock valued at $204,000 after acquiring an additional 5,645 shares during the period. Institutional investors and hedge funds own 25.25% of the company’s stock.

Several research firms recently issued reports on CODX. Zacks Investment Research cut shares of Co-Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Co-Diagnostics in a research note on Friday.

CODX opened at $9.53 on Tuesday. The stock has a market cap of $275.32 million, a P/E ratio of 6.15 and a beta of -3.60. The firm has a fifty day moving average price of $9.95 and a 200 day moving average price of $9.55. Co-Diagnostics, Inc. has a 1 year low of $7.01 and a 1 year high of $20.69.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings results on Thursday, August 12th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.22 by $0.11. The company had revenue of $27.36 million during the quarter, compared to analyst estimates of $21.00 million. Co-Diagnostics had a net margin of 47.98% and a return on equity of 65.33%. Analysts forecast that Co-Diagnostics, Inc. will post 0.95 earnings per share for the current fiscal year.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

See Also: What are popular green investing opportunities?

Want to see what other hedge funds are holding CODX? Visit to get the latest 13F filings and insider trades for Co-Diagnostics, Inc. (NASDAQ:CODX).

Institutional Ownership by Quarter for Co-Diagnostics (NASDAQ:CODX)

Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with's FREE daily email newsletter.